Clinical Trials · NCT01676116
The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 438
- Start date
- Aug 2012
- Locations
- 109 sites, 5 countries
- Primary endpoint
- Change in Glycosylated Haemoglobin (HbA1c) From Baseline (Randomisation, Visit 2)